Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 8 |
| List of Tables | 10 | 2 |
| List of Figures | 12 | 2 |
| Travel Vaccines Market to 2019: Introduction | 14 | 1 |
| Overview | 14 | 1 |
| Travel Vaccines Market to 2019: Overview | 15 | 6 |
| Vaccine-Preventable Diseases | 15 | 1 |
| Types of Vaccines | 16 | 1 |
| Regulatory Framework | 17 | 1 |
| US | 17 | 1 |
| UK | 17 | 1 |
| France | 18 | 1 |
| Germany | 18 | 1 |
| Italy | 18 | 1 |
| Spain | 19 | 1 |
| Japan | 19 | 1 |
| Vaccine Manufacturing Process | 20 | 1 |
| Travel Vaccines Market to 2019: Market Characterization and Forecast | 21 | 6 |
| Revenue Forecast | 21 | 1 |
| Market Share by Vaccine Type | 22 | 1 |
| Market Share by Geography | 23 | 1 |
| Traveling Population | 24 | 1 |
| Drivers | 25 | 1 |
| Aging Population and Increase in Global Tourist Traffic | 25 | 1 |
| Novel Vaccine Technologies | 25 | 1 |
| New and Novel Vaccines Launches Targeting High-Risk Populations | 25 | 1 |
| Restraints | 26 | 1 |
| Vaccine Supply Shortage Issues | 26 | 1 |
| High Start-up Costs and Special Technical Expertise Requirements for Vaccine Production | 26 | 1 |
| Public Acceptance | 26 | 1 |
| Austerity Measures Leading to a Drop in Healthcare Funding | 26 | 1 |
| Travel Vaccines Market to 2019: Hepatitis A Vaccines | 27 | 7 |
| Disease Overview | 27 | 1 |
| Market Forecasts | 28 | 1 |
| US | 28 | 1 |
| Top Five European Countries | 29 | 1 |
| Japan | 30 | 1 |
| Cost of Vaccination | 31 | 1 |
| US | 31 | 1 |
| Top Five European Countries | 31 | 1 |
| Japan | 32 | 1 |
| Pipeline Analysis | 32 | 1 |
| Phase III (Inactive) | 33 | 1 |
| Preclinical and Discovery (Inactive) | 33 | 1 |
| Travel Vaccines Market to 2019: Hepatitis B Vaccines | 34 | 8 |
| Disease Overview | 34 | 1 |
| Market Forecasts | 35 | 1 |
| US | 35 | 1 |
| Top Five European Countries | 36 | 1 |
| Japan | 37 | 1 |
| Cost of Vaccination | 38 | 1 |
| US | 38 | 1 |
| Top Five European Countries | 38 | 1 |
| Japan | 39 | 1 |
| Pipeline Analysis | 39 | 1 |
| Registration and Phase III | 40 | 1 |
| Phase II | 40 | 1 |
| Phase I | 40 | 1 |
| Preclinical and Discovery | 41 | 1 |
| Travel Vaccines Market to 2019: Japanese Encephalitis Vaccines | 42 | 7 |
| Disease Overview | 42 | 1 |
| Market Forecasts | 43 | 1 |
| US | 43 | 1 |
| Top Five European Countries | 44 | 1 |
| Japan | 45 | 1 |
| Cost of Vaccination | 46 | 1 |
| US | 46 | 1 |
| Top Five European Countries | 46 | 1 |
| Japan | 47 | 1 |
| Pipeline Analysis | 47 | 1 |
| Registration | 48 | 1 |
| Preclinical and Discovery | 48 | 1 |
| Travel Vaccines Market to 2019: Meningococcal Vaccines | 49 | 6 |
| Disease Overview | 49 | 1 |
| Market Forecasts | 50 | 1 |
| US | 50 | 1 |
| Top Five European Countries | 51 | 1 |
| Cost of Vaccination | 52 | 1 |
| US | 52 | 1 |
| Top Five European Countries | 52 | 1 |
| Pipeline Analysis | 53 | 1 |
| Registration and Phase III | 53 | 1 |
| Phase II | 54 | 1 |
| Preclinical and Discovery | 54 | 1 |
| Travel Vaccines Market to 2019: Rabies Vaccines | 55 | 7 |
| Disease Overview | 55 | 1 |
| Market Forecasts | 56 | 1 |
| US | 56 | 1 |
| Top Five European Countries | 57 | 1 |
| Japan | 58 | 1 |
| Cost of Vaccination | 59 | 1 |
| US | 59 | 1 |
| Top Five European Countries | 59 | 1 |
| Japan | 60 | 1 |
| Pipeline Analysis | 60 | 1 |
| Phase II | 61 | 1 |
| Phase I | 61 | 1 |
| Preclinical | 61 | 1 |
| Travel Vaccines Market to 2019: Typhoid Vaccines | 62 | 5 |
| Disease Overview | 62 | 1 |
| Market Forecasts | 63 | 1 |
| US | 63 | 1 |
| Top Five European Countries | 64 | 1 |
| Cost of Vaccination | 65 | 1 |
| US | 65 | 1 |
| Top Five European Countries | 65 | 1 |
| Pipeline Analysis | 66 | 1 |
| Phase II | 66 | 1 |
| Preclinical | 66 | 1 |
| Travel Vaccines Market to 2019: Yellow Fever Vaccines | 67 | 7 |
| Disease Overview | 67 | 1 |
| Market Forecasts | 68 | 1 |
| US | 68 | 1 |
| Top Five European Countries | 69 | 1 |
| Japan | 70 | 1 |
| Cost of Vaccination | 71 | 1 |
| US | 71 | 1 |
| Top Five European Countries | 71 | 1 |
| Japan | 72 | 1 |
| Pipeline Analysis | 72 | 1 |
| Phase III | 73 | 1 |
| Phase I | 73 | 1 |
| Preclinical and Discovery | 73 | 1 |
| Travel Vaccines Market to 2019: Competitive Landscape | 74 | 6 |
| Introduction | 74 | 1 |
| Major Company Profiles | 74 | 1 |
| GlaxoSmithKline | 74 | 1 |
| SWOT Analysis | 75 | 1 |
| Sanofi | 76 | 1 |
| SWOT Analysis | 76 | 1 |
| Pfizer | 77 | 1 |
| SWOT Analysis | 77 | 1 |
| Merck | 78 | 1 |
| SWOT Analysis | 78 | 1 |
| Novartis | 79 | 1 |
| SWOT Analysis | 79 | 1 |
| Travel Vaccines Market to 2019: Strategic Consolidations | 80 | 5 |
| Deals by Year | 80 | 1 |
| Deals by Type | 81 | 1 |
| Deals by Value | 82 | 1 |
| Deals by Geography | 83 | 1 |
| Summary of Major M&A Deals | 83 | 1 |
| Gilead Sciences Completes Acquisition of Pharmasset for $11.2 Billion | 83 | 1 |
| Johnson &Johnson Acquires Crucell | 84 | 1 |
| Summary of Major Licensing Deals | 84 | 1 |
| Intercell Enters into Licensing Agreement with Novartis for IC51 | 84 | 1 |
| Gilead Sciences Enters into Licensing Agreement with GlobeImmune | 84 | 1 |
| Vaccines in Asia-Pacific India, China and Australia: Overview | 85 | 26 |
| India | 85 | 1 |
| Regulatory Framework | 85 | 1 |
| National Health Policy 2002 | 85 | 1 |
| National Rural Health Mission | 85 | 1 |
| National Urban Health Mission | 86 | 1 |
| Immunization Schedule | 86 | 2 |
| Major Vaccine Brands by Indication | 88 | 3 |
| Major Company Profiles | 91 | 1 |
| Shantha Biotech | 91 | 1 |
| Serum Institute | 91 | 1 |
| Haffkine Biopharmaceuticals | 91 | 1 |
| Indian Immunologicals | 91 | 1 |
| Biological E | 92 | 1 |
| Recent Developments | 92 | 1 |
| Biological E. Launches Japanese Encephalitis Vaccine Jeev in India September 2012 | 92 | 1 |
| Approvals by Central Drugs Standard Control Organization | 92 | 1 |
| China | 92 | 1 |
| Regulatory Framework | 92 | 1 |
| State Food and Drug Administration | 92 | 1 |
| Center for Drug Evaluation | 93 | 1 |
| National Development and Reform Commission | 93 | 1 |
| National Institute for the Control of Pharmaceutical and Biological Products | 94 | 1 |
| Expanded Programme on Immunization | 94 | 1 |
| Major Company Profiles | 95 | 1 |
| Hualan Biological | 95 | 1 |
| Tiantan Biological | 95 | 1 |
| Liaoning Chengda | 96 | 1 |
| Zhifei Biological | 96 | 1 |
| China National Pharmaceutical Group Corporation (Sinopharm) | 96 | 1 |
| Australia | 97 | 1 |
| Regulatory Framework | 97 | 1 |
| Overview of Regulatory Agencies | 97 | 1 |
| New Drug Approval Process | 97 | 1 |
| Designated Vaccines and Circumstances in which Vaccines may be Provided | 98 | 1 |
| Designated Bacterial Vaccines and Circumstances in which Vaccines may be Provided | 98 | 2 |
| Designated Viral Vaccines and Circumstances in which Vaccines may be Provided | 100 | 3 |
| Designated Combined Bacterial and Viral Vaccines and Circumstances in which Vaccines may be Provided | 103 | 1 |
| Immunization Schedule | 104 | 1 |
| Major Company Profiles | 105 | 1 |
| CSL Limited | 105 | 1 |
| BioDiem | 105 | 1 |
| Virax | 106 | 1 |
| Recent Developments | 106 | 1 |
| Sanofi Pasteur Launches First Single-dose Vaccine against Japanese Encephalitis, Imojev, in Australia December 2012 | 106 | 1 |
| Fund Extension of HPV National Immunization Program | 106 | 1 |
| Vaccines in Emerging Markets: Strategic Consolidations | 107 | 1 |
| Deals by Year | 107 | 1 |
| Deals by Type | 108 | 1 |
| Deals by Value | 109 | 1 |
| Vaccines in Emerging Markets: Pipeline by Phase | 110 | 1 |
| Travel Vaccines Market to 2019: Appendix | 111 | 6 |
| Market Definitions | 111 | 1 |
| Abbreviations | 111 | 1 |
| Bibliography | 112 | 1 |
| Research Methodology | 113 | 3 |
| Coverage | 113 | 1 |
| Secondary Research | 113 | 1 |
| Primary Research | 114 | 1 |
| Model for Estimation of Vaccine Market | 114 | 2 |
| Geographical Landscape | 116 | 1 |
| Pipeline Analysis | 116 | 1 |
| Competitive Landscape | 116 | 1 |
| Expert Panel Validation | 116 | 1 |
| Contact Us | 116 | 1 |
| Disclaimer | 116 | 1 |
